Skip to main content

Table 4 Spearman correlations between changes from baseline to 4 weeks (ApoE4 noncarriers)

From: Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease

Measure

Brain region

r Value

95 % CI

p Value

Cholesterol change

Composite SUVr

−0.66

(−1.00, 0.39)

0.16

 

Frontal medial orbital

−0.54

(−1.00, 0.62)

0.27

 

Anterior cingulate

−0.66

(−1.00, 0.39)

0.16

 

Parietal

−0.89

(−1.00, −0.24)

0.019

 

Posterior cingulate

−0.66

(−1.00, 0.39)

0.16

 

Precuneus

−0.66

(−1.00, 0.39)

0.16

 

Temporal

−0.66

(−1.00, 0.39)

0.16

Triglycerides change

Composite SUVr

−0.89

(−1.00, −0.24)

0.019

 

Frontal medial orbital

−0.77

(−1.00, 0.11)

0.072

 

Anterior cingulate

−0.83

(−1.00, −0.05)

0.042

 

Parietal

−1.00

(−1.00, −1.00)

 
 

Posterior cingulate

−0.89

(−1.00, −0.24)

0.019

 

Precuneus

−0.89

(−1.00, −0.24)

0.019

 

Temporal

−0.89

(−1.00, −0.24)

0.019

1–42 change

Composite SUVr

−0.83

(−1.00, −0.05)

0.042

 

Frontal medial orbital

−0.71

(−1.00, 0.26)

0.11

 

Anterior cingulate

−0.94

(−1.00, −0.48)

0.005

 

Parietal

−0.54

(−1.00, 0.62)

0.27

 

Posterior cingulate

−0.83

(−1.00, −0.05)

0.042

 

Precuneus

−0.83

(−1.00, −0.05)

0.042

 

Temporal

−0.83

(−1.00, −0.05)

0.042

1–40 change

Composite SUVr

−0.37

(−1.00, 0.92)

0.47

 

Frontal medial orbital

−0.31

(−1.00, 1.00)

0.54

 

Anterior cingulate

−0.26

(−1.00, 1.00)

0.62

 

Parietal

0.20

(−1.00, 1.00)

0.70

 

Posterior cingulate

−0.37

(−1.00, 0.92)

0.47

 

Precuneus

−0.37

(−1.00, 0.92)

0.47

 

Temporal

−0.37

(−1.00, 0.92)

0.47

  1. CI confidence interval, SUVr standardized uptake value ratio